Baroda BNP Paribas Health and Wellness Fund - Regular Plan - Growth
Baroda BNP Paribas Asset Management India Pvt. Ltd.
₹10.26 (+1.08%)
NAV as of 9 Oct 2026
Minimum Investment: ₹1,000
Return
6.22% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.30%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹1,000
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,118
Invested ₹1,000
▲+11.81%1 year
₹1,062
Invested ₹1,000
▲+6.22%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | BSE Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +6.22% | — | — | — |
| Cumulative returns (%) | +6.22% | — | — | — |
Fund Manager
| Manager | Ankeet Pandya |
|---|---|
| Role | Manager |
| Manager Tenure | 0.23 yrs |
About Fund
| Date of Incorporation | 27 Jun 2025 |
|---|---|
| Fund House | Baroda BNP Paribas Asset Management India Pvt. Ltd. |
| Custodian | Deutsche Bank AG |
| Registrar / Transfer Agent | Baroda BNP Paribas Asset Management India Pvt. Ltd. |
| Address | 1 Great Winchester Street |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 9.01% |
| Divi's Laboratories Ltd | 8.01% |
| Torrent Pharmaceuticals Ltd | 7.99% |
| Mankind Pharma Ltd | 7.41% |
| Max Healthcare Institute Ltd Ordinary Shares | 6.38% |
| Cipla Ltd | 6.32% |
| Ipca Laboratories Ltd | 6.23% |
| Lupin Ltd | 5.99% |
| Laurus Labs Ltd | 5.66% |
| Apollo Hospitals Enterprise Ltd | 5.44% |
| Abbott India Ltd | 5.43% |
| Aster DM Healthcare Ltd Ordinary Shares | 5.22% |
| J.B. Chemicals & Pharmaceuticals Ltd | 4.57% |
| Fortis Healthcare Ltd | 4.50% |
| Gland Pharma Ltd | 3.73% |
| AstraZeneca Pharma India Ltd | 3.56% |
| SBI Life Insurance Co Ltd | 3.45% |
| Glenmark Pharmaceuticals Ltd | 3.42% |
| Emcure Pharmaceuticals Ltd | 3.36% |
| Ajanta Pharma Ltd | 2.89% |
Investment Strategy
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Long term wealth creation
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.